| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/12/2008 | US7411072 e.g. 5-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-3H-benzooxazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia, Crohn's disease |
| 08/12/2008 | US7411055 Genetic engineering |
| 08/12/2008 | US7411001 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 08/12/2008 | US7410991 Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors |
| 08/12/2008 | US7410986 For therapy of inflammatory symptoms; tumors, ischemia and tumor |
| 08/12/2008 | US7410984 novel pyridone derivatives capable of inhibiting alpha 4 integrin mediated cell adhesion; to treat chronic inflammatory diseases; 3-(4-{2-Oxo-3-[4-(3-o-tolyl-ureido)phenyl]-2H-pyridin-1-ylmethyl}phenyl)propionic acid; hydrolysis |
| 08/12/2008 | US7410983 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 08/12/2008 | US7410962 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| 08/12/2008 | US7410959 To treat obesity or diabetes; reduction of serum cholesterol and the treatment of atherosclerosis |
| 08/12/2008 | US7410955 Therapeutic use of agonist ligands specific to G2A receptor |
| 08/12/2008 | US7410652 Controlled release and taste masking oral pharmaceutical composition |
| 08/12/2008 | US7410651 Controlled release and taste masking oral pharmaceutical composition |
| 08/12/2008 | US7410647 Vaccines |
| 08/12/2008 | US7410642 Assays and therapies for latent viral infection |
| 08/12/2008 | US7410641 Hybridoma and monoclonal antibodies produced; insulin-like growth factor (IGF); diagnosis, treatment, prevention of diabetes and metabolic disorders |
| 08/12/2008 | CA2376236C Modification of biological elements |
| 08/12/2008 | CA2359819C 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 08/07/2008 | WO2008094909A2 Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| 08/07/2008 | WO2008094869A1 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders |
| 08/07/2008 | WO2008094574A2 Furanone compounds and methods of making and using the same |
| 08/07/2008 | WO2008094054A2 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders |
| 08/07/2008 | WO2008093848A1 Composition for decreasing inflammation marker comprising phosphatidylcholine |
| 08/07/2008 | WO2008093825A1 Caffeine analog |
| 08/07/2008 | WO2008093737A1 Amide derivative |
| 08/07/2008 | WO2008093691A1 Protective agent for retinal nerve or optic nerve |
| 08/07/2008 | WO2008093677A1 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibiting activity |
| 08/07/2008 | WO2008093674A1 Novel thiadiazole derivative having kinase inhibitory activity |
| 08/07/2008 | WO2008093646A1 Peptide capable of activating wnt signaling |
| 08/07/2008 | WO2008093464A1 Animal having modification in mgat2 gene |
| 08/07/2008 | WO2008093350A1 Novel anhydrous crystalline form of carvedilol dihydrogen phosphate |
| 08/07/2008 | WO2008092292A1 Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
| 08/07/2008 | WO2008092257A1 Use of catecholamines and related compounds as anti-angiogenic agents |
| 08/07/2008 | WO2008092231A1 Compounds for the prevention and treatment of cardiovascular diseases |
| 08/07/2008 | WO2008092199A1 Thiopyrimidine-based compounds and uses thereof |
| 08/07/2008 | WO2008077094A3 Methods for promoting neovascularization |
| 08/07/2008 | WO2008074413A3 Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase |
| 08/07/2008 | WO2008016924A3 Identification of a micro-rna that activates expression of beta-myosin heavy chain |
| 08/07/2008 | WO2007140222A3 Pyrrolopyrimidine compounds and their uses |
| 08/07/2008 | WO2007120709A3 Methods and compositions for treatment of lesioned sites of body vessels |
| 08/07/2008 | US20080188563 Blood fluidity improving agent |
| 08/07/2008 | US20080188547 Uses of ion channel modulating compounds |
| 08/07/2008 | US20080188546 Preventive or therapeutic agents for decubitus |
| 08/07/2008 | US20080188545 (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions |
| 08/07/2008 | US20080188543 {1-Methyl-6-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid; deep vein thrombosis and coronary heart disease, Alzheimer's disease and pulmonary fibrosis |
| 08/07/2008 | US20080188542 Novel indole polymorphs |
| 08/07/2008 | US20080188539 Ramipril-amino acid salts |
| 08/07/2008 | US20080188533 Dual-acting antihypertensive agents |
| 08/07/2008 | US20080188531 Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries |
| 08/07/2008 | US20080188528 Modulators of C3a receptor and methods of use thereof |
| 08/07/2008 | US20080188521 Novel pharmaceutical compounds |
| 08/07/2008 | US20080188520 e.g. 1-(2-Cyclopropylmethoxy-1,2-diphenylethyl)-1H-pyridin-2-one; potassium (K+) channel-blocking agent; potassium channel KACh and TASK-1 channel blocking agent; atrial arrhythmias, atrial fibrillation or atrial flutter; respiratory disorders, neurodegenerative disorders; anticarcinogenic agent |
| 08/07/2008 | US20080188519 Novel azacyclic ethynyl derivatives |
| 08/07/2008 | US20080188517 Crystalline forms of a factor xa inhibitor |
| 08/07/2008 | US20080188514 e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection |
| 08/07/2008 | US20080188497 Combination regime; preventing stroke or reducing the risk of stroke or secondary stroke |
| 08/07/2008 | US20080188496 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| 08/07/2008 | US20080188477 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them |
| 08/07/2008 | US20080188476 Comprises zonisamide (anticonvulsant) in combination with bupropion for enhancing activity of norepinephrine and/or dopamine via uptake inhibition; side effect reduction |
| 08/07/2008 | US20080188473 Indoles Useful in the Treatment of Inflammation |
| 08/07/2008 | US20080188472 Indole-2-Carboxylic Acid Hydrazides |
| 08/07/2008 | US20080188467 Compounds for the prevention and treatment of cardiovascular diseases |
| 08/07/2008 | US20080188426 Sodium dependent glucose transporter inhibition; hyperglycemia associated diseases; 3-glucopyranosyloxy- 1H-indazole and 1H-pyrazolo[3,4-b]pyridine derivatives |
| 08/07/2008 | US20080188425 Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods |
| 08/07/2008 | US20080188422 Peptides having separate domains; AIDS, cardiovascular disease, hepatitis. diabetes, cancer; side effect reduction |
| 08/07/2008 | US20080188417 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 08/07/2008 | US20080188409 Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof |
| 08/07/2008 | US20080188402 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| 08/07/2008 | US20080187961 Polynucleotides encoding signal peptide-containing molecules |
| 08/07/2008 | US20080187622 Method for manufacturing alpha-glycosylisoquercitrin, intermediate product and by-product thereof |
| 08/07/2008 | US20080187608 Blocking nuclear factor kappa beta, oxidation stresses and endothelins receptors |
| 08/07/2008 | US20080187579 Extended-release dosage form |
| 08/07/2008 | US20080187575 Pyrimidine Derivatives |
| 08/07/2008 | US20080187570 Improve tissue response at site of implant; containing polynucleotide and cation |
| 08/07/2008 | US20080187493 Peptide-Based Compounds |
| 08/07/2008 | CA2702647A1 Thiopyrimidine-based compounds and uses thereof |
| 08/07/2008 | CA2676984A1 Compounds for the prevention and treatment of cardiovascular diseases |
| 08/07/2008 | CA2676163A1 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
| 08/07/2008 | CA2675450A1 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders |
| 08/07/2008 | CA2675148A1 Use of catecholamines and related compounds as anti-angiogenic agents |
| 08/06/2008 | EP1953165A1 Aza-substituted spiro derivative |
| 08/06/2008 | EP1953159A1 6-Benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds useful as PDE5 inhibitors |
| 08/06/2008 | EP1953136A1 Derivatives of (-)-venlafaxine and methods of preparing and using the same |
| 08/06/2008 | EP1952826A1 Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor |
| 08/06/2008 | EP1951738A2 Further crystalline forms of rostafuroxin |
| 08/06/2008 | EP1951692A1 Oxazole and thiazole ppar modulator |
| 08/06/2008 | EP1951690A1 Heterocyclic cetp inhibitors |
| 08/06/2008 | EP1951687A1 N-hydroxyamide derivatives and use thereof |
| 08/06/2008 | EP1951676A2 Lxr modulators |
| 08/06/2008 | EP1951673A2 Heterocyclic cetp inhibitors |
| 08/06/2008 | EP1951672A1 Potassium channel inhibitors |
| 08/06/2008 | EP1951663A2 (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
| 08/06/2008 | EP1951309A2 Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| 08/06/2008 | EP1951291A1 Methods of regulating renalase (monoamine oxidase c) |
| 08/06/2008 | EP1951286A1 Combined use of dpp iv inhibitors and gastrin compounds |
| 08/06/2008 | EP1951264A2 Use of cicletanine and other furopyridines for treatment of hypertension |
| 08/06/2008 | EP1951254A2 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| 08/06/2008 | EP1951253A2 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| 08/06/2008 | EP1951251A2 Spirohydantoin aryl cgrp receptor antagonists |
| 08/06/2008 | EP1951227A2 Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
| 08/06/2008 | EP1951220A2 Compositions for lowering serum cholesterol and/or triglycerides |